Solvonis Therapeutics PLC

SVNS

Company Profile

  • Business description

    Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

  • Contact

    Eccleston Yards
    25 Eccleston Place
    LondonSW1W 9NF
    GBR

    T: +44 7795430246

    https://www.solvonis.com

  • Sector

    Industrials

    Stock type

    Sensitive

  • Industry

    Specialty Industrial Machinery

    Fiscal Year End

    31 December 2025

    Employees

    3

Stocks News & Analysis

stocks

Chart of the Week: Opportunities with wide-moat retailers

Consumer defensive names look undervalued.
stocks

New ASX share added to our best ideas

Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,240.3042.600.46%
CAC 408,075.76108.811.37%
DAX 4024,449.08335.461.39%
Dow JONES (US)46,441.1043.210.09%
FTSE 1009,453.256.820.07%
HKSE27,287.12431.561.61%
NASDAQ22,755.1695.150.42%
Nikkei 22544,936.73385.880.87%
NZX 50 Index13,451.7617.770.13%
S&P 5006,711.2022.740.34%
S&P/ASX 2008,945.9040.100.45%
SSE Composite Index3,882.7820.250.52%

Market Movers